Share：
Share this content in WeChat
X
[Chinese][PDF]4436
• Special Focus •
Different MRI features between BRCA mutant and non-mutant breast cancer patients
LIN Luyi  WANG Zezhou  XIAO Qin  HU Zhen  GU Yajia  YOU Chao 

Cite this article as: LIN L Y, WANG Z Z, XIAO Q, et al. Different MRI features between BRCA mutant and non-mutant breast cancer patients[J]. Chin J Magn Reson Imaging, 2024, 15(1): 21-27. DOI:10.12015/issn.1674-8034.2024.01.004.


[Abstract] Objective To investigate the relationship between MRI clinicopathological features and breast cancer susceptibility gene (BRCA) gene mutation in breast cancer.Materials and Methods Retrospective collection clinicopathological, MRI and prognosis data of 81 BRCA gene non-mutant breast cancer and 76 BRCA gene mutant breast cancer patients (including 38 BRCA1 gene mutation and 38 BRCA2 gene mutation) diagnosed and detected BRCA gene status by next generation sequencing technology in Fudan University Shanghai Cancer Center from June 2011 to July 2017. Chi-square test, Fisher's exact test and multivariate logistic regression were used to analyze the differences of clinicopathologic and MRI features between BRCA gene mutant and non-mutant, BRCA1 gene mutant and BRCA2 gene mutant breast cancer patients.Results There was a statistically significant difference in the distribution of histological types between BRCA gene mutation group and non-mutant breast cancer (P=0.037). The proportion of BRCA-mutated breast cancer with invasive ductal carcinoma (IDC) was high, and the proportion of BRCA1 and BRCA2 mutated breast cancer with IDC was 92.11% and 94.74%, respectively. In univariate analysis, BRCA non-mutant breast cancer was more performed as I+Ⅱ other than type Ⅲ enhancement curve (P=0.041). There was a statistically significant difference in the distribution of mass lesions between BRCA1 gene mutation breast cancer and BRCA2 gene mutation breast cancer (P=0.030). The proportion of BRCA2 gene mutation lesions showing irregular shape was higher, accounting for 87.10% of BRCA2 gene mutation lesions showing mass type. There was no significant difference in fibroglandular composition and BPE characteristics between BRCA mutated and non-mutated breast cancer.Conclusions Histology, molecular subtype and Ki-67 index were different in BRCA mutant and non-mutant breast cancer. Lesion type and enhancement curve type on MRI were also associated with BRCA gene status in univariate analysis.
[Keywords] breast cancer；BRCA gene mutation；distinguish；morphological characteristics of the lesions；enhancement curve；magnetic resonance imaging

LIN Luyi1, 2   WANG Zezhou2, 3   XIAO Qin1, 2   HU Zhen2, 4   GU Yajia1, 2   YOU Chao1, 2*  

1 Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

3 Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai 200032, China

4 Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China

Corresponding author: YOU C, E-mail: youchao8888@aliyun.com

Conflicts of interest   None.

Received  2023-10-10
Accepted  2023-12-29
DOI: 10.12015/issn.1674-8034.2024.01.004
Cite this article as: LIN L Y, WANG Z Z, XIAO Q, et al. Different MRI features between BRCA mutant and non-mutant breast cancer patients[J]. Chin J Magn Reson Imaging, 2024, 15(1): 21-27. DOI:10.12015/issn.1674-8034.2024.01.004.

[1]
LEE A, MOON B I, KIM T H. BRCA1/BRCA2 pathogenic variant breast cancer: treatment and prevention strategies[J]. Ann Lab Med, 2020, 40(2): 114-121. DOI: 10.3343/alm.2020.40.2.114.
[2]
WANG Y A, JIAN J W, HUNG C F, et al. Germline breast cancer susceptibility gene mutations and breast cancer outcomes[J/OL]. BMC Cancer, 2018, 18(1): 315 [2023-10-09]. https://pubmed.ncbi.nlm.nih.gov/29566657/. DOI: 10.1186/s12885-018-4229-5.
[3]
KOTSOPOULOS J. BRCA mutations and breast cancer prevention[J/OL]. Cancers, 2018, 10(12): 524 [2023-10-09]. https://pubmed.ncbi.nlm.nih.gov/30572612/. DOI: 10.3390/cancers10120524.
[4]
RAKHA E A, REIS-FILHO J S, ELLIS I O. Basal-like breast cancer: a critical review[J]. J Clin Oncol, 2008, 26(15): 2568-2581. DOI: 10.1200/jco.2007.13.1748.
[5]
BODDICKER N J, HU C L, WEITZEL J N, et al. Risk of late-onset breast cancer in genetically predisposed women[J]. J Clin Oncol, 2021, 39(31): 3430-3440. DOI: 10.1200/jco.21.00531.
[6]
CHEN L Y, SUN J, WAN Q T, et al. Comparison of clinicopathological characteristics between BRCA1 and BRCA2 muta-tion carriers among Chinese women with breast cancer[J]. Chin J Clin Oncol, 2022, 49(23): 1224-1229. DOI: 10.12354/j.issn.1000-8179.2022.20221002.
[7]
FOULKES W D, METCALFE K, SUN P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type[J]. Clin Cancer Res, 2004, 10(6): 2029-2034. DOI: 10.1158/1078-0432.ccr-03-1061.
[8]
SHAO F P, DUAN Y Y, ZHAO Y H, et al. PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival[J]. Aging, 2021, 13(6): 8975-8988. DOI: 10.18632/aging.202724.
[9]
CORTESI L, RUGO H S, JACKISCH C. An overview of PARP inhibitors for the treatment of breast cancer[J]. Target Oncol, 2021, 16(3): 255-282. DOI: 10.1007/s11523-021-00796-4.
[10]
TUTT A N J, GARBER J E, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25): 2394-2405. DOI: 10.1056/NEJMoa2105215.
[11]
PAUL A, PAUL S. The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers[J]. Front Biosci (Landmark Ed), 2014, 19(4): 605-618. DOI: 10.2741/4230.
[12]
HUANG X N, JIANG Y L, HUANG W C. Research progress of multiparametric MRI radiomics in breast cancer[J]. Chin J Magn Reson Imag, 2023, 14(6): 151-155. DOI: 10.12015/issn.1674-8034.2023.06.027.
[13]
DAI T, SU T, WANG R, et al. Predictive value of DCE-MRI features of breast cancer on hormone receptor, HER-2 and triple negative breast cancer[J]. Chin J Magn Reson Imag, 2023, 14(4): 57-67. DOI: 10.12015/issn.1674-8034.2023.04.011.
[14]
NIU W, LUO Y H, YU T, et al. The value of tumor hemodynamics and morphological features in predicting the postoperative recurrence time of breast cancer based on dynamic contrast-enhanced MRI[J]. Chin J Radiol, 2020, 54(3): 209-214. DOI: 10.3760/cma.j.issn.1005-1201.2020.03.007.
[15]
NARANJO I D, SOGANI J, SACCARELLI C, et al. MRI screening of BRCA mutation carriers: comparison of standard protocol and abbreviated protocols with and without T2-weighted images[J]. AJR Am J Roentgenol, 2022, 218(5): 810-820. DOI: 10.2214/AJR.21.27022.
[16]
KRAMMER J, PINKER-DOMENIG K, ROBSON M E, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers[J]. Breast Cancer Res Treat, 2017, 163(3): 565-571. DOI: 10.1007/s10549-017-4198-4.
[17]
SUNG J S, STAMLER S, BROOKS J, et al. Breast cancers detected at screening MR imaging and mammography in patients at high risk: method of detection reflects tumor histopathologic results[J]. Radiology, 2016, 280(3): 716-722. DOI: 10.1148/radiol.2016151419.
[18]
VEGUNTA S, BHATT A A, CHOUDHERY S A, et al. Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging[J]. Breast Cancer, 2022, 29(1): 19-29. DOI: 10.1007/s12282-021-01298-x.
[19]
PLEVRITIS S K, KURIAN A W, SIGAL B M, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging[J]. JAMA, 2006, 295(20): 2374-2384. DOI: 10.1001/jama.295.20.2374.
[20]
HA S M, CHAE E Y, CHA J H, et al. Association of BRCA mutation types, imaging features, and pathologic findings in patients with breast cancer with BRCA1 and BRCA2 mutations[J]. AJR Am J Roentgenol, 2017, 209(4): 920-928. DOI: 10.2214/AJR.16.16957.
[21]
MURAKAMI W, TOZAKI M, NAKAMURA S, et al. The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan[J]. Breast Cancer, 2019, 26(5): 552-561. DOI: 10.1007/s12282-019-00955-6.
[22]
LEWIN A A, KIM S G, BABB J S, et al. Assessment of background parenchymal enhancement and lesion kinetics in breast MRI of BRCA 1/2 mutation carriers compared to matched controls using quantitative kinetic analysis[J]. Acad Radiol, 2016, 23(3): 358-367. DOI: 10.1016/j.acra.2015.11.011.
[23]
COMSTOCK C, SUNG J S. BI-RADS 3 for magnetic resonance imaging[J]. Magn Reson Imaging Clin N Am, 2013, 21(3): 561-570. DOI: 10.1016/j.mric.2013.04.006.
[24]
SAIFI O, CHAHROUR M A, LI Z, et al. Is breast conservation superior to mastectomy in early stage triple negative breast cancer?[J/OL]. Breast, 2022, 62: 144-151 [2023-10-09]. https://pubmed.ncbi.nlm.nih.gov/35182994/. DOI: 10.1016/j.breast.2022.02.006.
[25]
ARPINO G, PENSABENE M, CONDELLO C, et al. Tumor characteristics and prognosis in familial breast cancer[J/OL]. BMC Cancer, 2016, 16(1): 924 [2023-10-09]. https://pubmed.ncbi.nlm.nih.gov/27899083/. DOI: 10.1186/s12885-016-2962-1.
[26]
ZHU X Y, TIAN T, CAI X, et al. Comparative study on the pathological features of BRCA1/2 mutation and non-BRCA1/2 mutation breast cancers in China[J]. China Oncol, 2019, 29(2): 142-147. DOI: 10.19401/j.cnki.1007-3639.2019.02.008.
[27]
NOH J M, HAN B K, CHOI D H, et al. Association between BRCA mutation status, pathological findings, and magnetic resonance imaging features in patients with breast cancer at risk for the mutation[J]. J Breast Cancer, 2013, 16(3): 308-314. DOI: 10.4048/jbc.2013.16.3.308.
[28]
LI Y, ZHANG X X, QIU J L, et al. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis[J]. J BUON, 2019, 24(6): 2361-2368.
[29]
SEKI A, TSUNODA H, TAKEI J, et al. Clinicopathological and imaging features ofductal carcinoma in situ in BRCA1/2 mutation carriers[J]. Breast Dis, 2023, 42(1): 5-15. DOI: 10.3233/BD-220006.
[30]
TAKAOKA M, MIKI Y. BRCA1 gene: function and deficiency[J]. Int J Clin Oncol, 2018, 23(1): 36-44. DOI: 10.1007/s10147-017-1182-2.
[31]
KUHL C, WEIGEL S, SCHRADING S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial[J]. J Clin Oncol, 2010, 28(9): 1450-1457. DOI: 10.1200/JCO.2009.23.0839.
[32]
ZHAO Y L, ZHAO N, CHEN T, et al. MRI features of triple-negative breast cancer and non-triple negative breast cancer[J]. Chin J CT MRI, 2021, 19(12): 81-83, 159. DOI: 10.3969/j.issn.1672-5131.2021.12.025.
[33]
LIU S H, SHAO S, WEI K J, et al. Diagnostic value of DCE-MRI combined with DKI in predicting the triple negative breast cancer[J]. Chin J Magn Reson Imag, 2023, 14(5): 110-115. DOI: 10.12015/issn.1674-8034.2023.05.020.
[34]
ZHAO R, MA W J, TANG J, et al. Heterogeneity of enhancement kinetics in dynamic contrast-enhanced MRI and implication of distant metastasis in invasive breast cancer[J/OL]. Clin Radiol, 2020, 75(12): 961.e25-961.961.e32 [2023-10-09]. https://pubmed.ncbi.nlm.nih.gov/32859381/. DOI: 10.1016/j.crad.2020.07.030.

PREV Application value of IDEAL-IQ sequence in differential diagnosis of benign and malignant breast masses
NEXT Value of radiomics model based on spatiotemporal heterogeneity of MRI to predict pathological complete response in triple-negative breast cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn